Testing minocycline added to usual medicine for adults with depression
Tests minocycline added to usual medicine in adults with depression.
Plain-language title generated from the registry record
Registry title: Targeting inflammation in depression using Minocycline: a patient stratification approach using peripheral inflammatory biomarkers and MRI
Key facts
- Where
- Brescia, ItalySee the 2 sites
- Phase
- Phase 2
Where in Italy
- Azienda Socio Sanitaria Territoriale degli Spedali Civili di BresciaBrescia, ItalyNot yet recruiting
- Provincia Lombardo Veneta Dell’Ordine Ospedaliero Di San Giovanni Di Dio FatebenefratelliBrescia, ItalyNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Provincia Lombardo Veneta Dell’Ordine Ospedaliero Di San Giovanni Di Dio Fatebenefratelli
- Trial code
- NCT06207760EU 2024-520076-10-01
- Record updated
- 9 November 2026
- Original description
To evaluate an improvement in the peripheral inflammatory status in depressed patients after 8 weeks of treatment with Minocycline in addition to their current pharmacological treatmentRead full original descriptionShow less
Targeting inflammation in depression using Minocycline: a patient stratification approach using peripheral inflammatory biomarkers and MRI
To evaluate an improvement in the peripheral inflammatory status in depressed patients after 8 weeks of treatment with Minocycline in addition to their current pharmacological treatment
Inclusion: Being male or female depressed patients (aged 18-65); 2. Having a current DSM-V diagnosis of nonpsychotic major depressive disorder confirmed by SCID; 3. Being non-responder to a current SSRI for at least 8 weeks, and historically to one other SSRI; 4. Being in stable antidepressant therapy for at least 8 weeks; 5. Being tolerant to the current SSRI; 6. Accepting Minocycline treatment; 7. Having CPR level> 2 mg/L; 8. Having signed and dated an informed consent to participate in the study; 9. Having no contraindications to receive treatment with Minocycline.
Exclusion: Having active suicidal ideation; 2. Having a primary diagnosis of bipolar disorder, obsessive-compulsive disorder, eating disorder, PTSD; 3. Having a history of substance/alcohol abuse; 4. Having received tetracycline therapy within the previous 2 months; 5. Having a history of sensitivity to this class of drugs; 6. Having acute infections or an autoimmune or inflammatory disorder; 7. Having CRP>20 mg/L, as indicates acute infection or other major pathology; 8. Being sensitive to Minocycline; 9. Having a history of severe allergy or hypersensitivity to drugs; 10. Being hypersensitive to the active substance, to other tetracyclines or to any of the excipients; 11. Having severe renal failure; 12. Having hepatic dysfunction; 13. Being pregnant and in lactation; 14. (for MRI) Having pacemakers, electromechanical devices, ferromagnetic vascular clips, cochlear implants, stapedial prostheses, ferromagnetic foreign bodies, sickle cell anemia.